Chemotherapy Research Today is a free monthly online journal that collates and summarizes the latest research about Chemotherapy, including details on cancer treatment, side effects, drugs.

Volume 4 (2007), Issue 10 (October)

1. Phase III randomized trial of intravenous cisplatin plus a 24- or 96-hour infusion of paclitaxel in epithelial ovarian cancer: a Gynecologic Oncology Group Study.
   J Clin Oncol, 25(28): 4466-71. [Abstract] [Full-text]
2. Measurement of residual breast cancer burden to predict survival after neoadjuvant chemotherapy.
   J Clin Oncol, 25(28): 4414-22. [Abstract] [Full-text]
3. Phase II PETHEMA trial of alternating bortezomib and dexamethasone as induction regimen before autologous stem-cell transplantation in younger patients with multiple myeloma: efficacy and clinical implications of tumor response kinetics.
   J Clin Oncol, 25(28): 4452-8. [Abstract] [Full-text]
4. Melphalan, prednisone, and lenalidomide treatment for newly diagnosed myeloma: a report from the GIMEMA--Italian Multiple Myeloma Network.
   J Clin Oncol, 25(28): 4459-65. [Abstract] [Full-text]
5. Herpes zoster infection as an immune reconstitution inflammatory syndrome in HIV-seropositive subjects: a review.
   Oral Surg Oral Med Oral Pathol Oral Radiol Endod, 104(4): 455-60. [Abstract] [Full-text]
6. Clinical trial of interconceptional antibiotics to prevent preterm birth: subgroup analyses and possible adverse antibiotic-microbial interaction.
   Am J Obstet Gynecol, 197(4): 367.e1-6. [Abstract] [Full-text]
7. Neoadjuvant chemotherapy plus radical surgery in locally advanced cervical cancer during pregnancy: a case report.
   Am J Obstet Gynecol, 197(4): e5-6. [Abstract] [Full-text]
8. Long-term clinical outcomes with sirolimus-eluting coronary stents: five-year results of the RAVEL trial.
   J Am Coll Cardiol, 50(14): 1299-304. [Abstract] [Full-text]
9. Clinical application of airway bypass with paclitaxel-eluting stents: early results.
   J Thorac Cardiovasc Surg, 134(4): 974-81. [Abstract] [Full-text]
10. Relationship between ornithine decarboxylase levels in anaplastic gliomas and progression-free survival in patients treated with DFMO-PCV chemotherapy.
    Int J Cancer, 121(10): 2279-83. [Abstract] [Full-text]
11. Design of phase II cancer trials using a continuous endpoint of change in tumor size: application to a study of sorafenib and erlotinib in non small-cell lung cancer.
    J Natl Cancer Inst, 99(19): 1455-61. [Abstract] [Full-text]
12. Irinotecan-cisplatin therapy for patients with extensive-stage small cell lung cancer: use patterns among American medical oncologists 2000-2006.
    J Thorac Oncol, 2(10): 953-6. [Abstract] [Full-text]
13. Comparison of docetaxel- and vinca alkaloid-based chemotherapy in the first-line treatment of advanced non-small cell lung cancer: a meta-analysis of seven randomized clinical trials.
    J Thorac Oncol, 2(10): 939-46. [Abstract] [Full-text]
14. Docetaxel and exisulind in previously treated non-small cell lung cancer (NSCLC) patients: a multicenter, phase II clinical trial.
    J Thorac Oncol, 2(10): 933-8. [Abstract] [Full-text]
15. Phase II multicenter trial with carboplatin and gemcitabine induction chemotherapy followed by radiotherapy concomitantly with low-dose paclitaxel and gemcitabine for stage IIIA and IIIB non-small cell lung cancer.
    J Thorac Oncol, 2(10): 927-32. [Abstract] [Full-text]
16. Restaging of mediastinal nodes with transbronchial needle aspiration after induction chemoradiation for locally advanced non-small cell lung cancer.
    J Thorac Oncol, 2(10): 912-5. [Abstract] [Full-text]
17. ERCC1 mRNA expression is not associated with response and survival after platinum-based chemotherapy regimens in advanced non-small cell lung cancer.
    J Thorac Oncol, 2(10): 902-6. [Abstract] [Full-text]
18. Efficacy of highly active antiretroviral therapy in HIV-1 infected children in Kenya.
    Pediatrics, 120(4): e856-61. [Abstract] [Full-text]
19. The multikinase inhibitor sorafenib potentiates TRAIL lethality in human leukemia cells in association with Mcl-1 and cFLIPL down-regulation.
    Cancer Res, 67(19): 9490-500. [Abstract] [Full-text]
20. Targeting cyclooxygenase-2 and the epidermal growth factor receptor for the prevention and treatment of intestinal cancer.
    Cancer Res, 67(19): 9380-8. [Abstract] [Full-text]
21. c-Jun N-terminal kinases as potential therapeutic targets.
    Expert Opin Ther Targets, 11(10): 1339-53. [Abstract] [Full-text]
22. Targeting PGC-1 alpha to control energy homeostasis.
    Expert Opin Ther Targets, 11(10): 1329-38. [Abstract] [Full-text]
23. Focal adhesion kinase: a promising target for anticancer therapy.
    Expert Opin Ther Targets, 11(10): 1315-28. [Abstract] [Full-text]
24. Tackling EGFR signaling with TACE antagonists: a rational target for metalloprotease inhibitors in cancer.
    Expert Opin Ther Targets, 11(10): 1287-98. [Abstract] [Full-text]
25. Targeting systemic inflammation: novel therapies for the treatment of chronic obstructive pulmonary disease.
    Expert Opin Ther Targets, 11(10): 1273-86. [Abstract] [Full-text]
26. Pilot study of an outpatient-based approach for advanced lymphoma using vinorelbine, gemcitabine and filgrastim.
    Intern Med J, 37(11): 760-6. [Abstract] [Full-text]
27. Epidemiology, pathogenesis, and management of Clostridium difficile infection.
    Dig Dis Sci, 52(11): 2958-62. [Abstract] [Full-text]
28. Phase II trial of irinotecan, cisplatin and mitomycin for relapsed small cell lung cancer.
    Int J Cancer, 121(11): 2575-7. [Abstract] [Full-text]
29. Third-line therapy for metastatic colorectal cancer.
    Cancer Chemother Pharmacol, 61(1): 1-13. [Abstract] [Full-text]
30. A phase II trial of modified weekly irinotecan and cisplatin for chemotherapy-naïve patients with metastatic or recurrent squamous cell carcinoma of the esophagus.
    Cancer Chemother Pharmacol, 61(1): 83-8. [Abstract] [Full-text]
31. The gemcitabine, docetaxel, and capecitabine (GTX) regimen for metastatic pancreatic cancer: a retrospective analysis.
    Cancer Chemother Pharmacol, 61(1): 167-75. [Abstract] [Full-text]
32. Neurotoxicity of FOLFOX-4 as adjuvant treatment for patients with colon and gastric cancer: a randomized study of two different schedules of oxaliplatin.
    Cancer Chemother Pharmacol, 61(1): 105-11. [Abstract] [Full-text]
33. A phase I study of capecitabine and a modulatory dose of irinotecan in metastatic breast cancer.
    Cancer Chemother Pharmacol, 61(1): 125-31. [Abstract] [Full-text]
34. Capecitabine and doxorubicin combination chemotherapy as salvage therapy in pretreated advanced gastric cancer.
    Cancer Chemother Pharmacol, 61(1): 157-65. [Abstract] [Full-text]
35. Pharmacometrics and delivery of novel nanoformulated PEG-b-poly(epsilon-caprolactone) micelles of rapamycin.
    Cancer Chemother Pharmacol, 61(1): 133-44. [Abstract] [Full-text]
36. Docetaxel, low-dose estramustine, and doxifluridine in hormone-refractory metastatic prostate cancer.
    Cancer Chemother Pharmacol, 61(1): 53-61. [Abstract] [Full-text]
37. The combination of capecitabine and irinotecan in treating 5-Fluorouracil- and Oxaliplatin-pretreated metastatic colorectal cancer.
    Cancer Chemother Pharmacol, 61(1): 75-81. [Abstract] [Full-text]
38. Phase II trial of gemcitabine combined with cisplatin in patients with inoperable biliary tract carcinomas.
    Cancer Chemother Pharmacol, 61(1): 47-52. [Abstract] [Full-text]
39. Acute anterior myocardial infarction after chemotherapy for testicular seminoma in a young patient.
    Clin Appl Thromb Hemost, 13(4): 439-42. [Abstract] [Full-text]
40. Concomitant intensive chemoradiotherapy induction in non-metastatic inflammatory breast cancer: long-term follow-up.
    Br J Cancer, 97(7): 883-7. [Abstract] [Full-text]
41. Phase I study of S-1, docetaxel and cisplatin combination chemotherapy in patients with unresectable metastatic gastric cancer.
    Br J Cancer, 97(7): 851-6. [Abstract] [Full-text]
42. [18F]2-fluoro-2-deoxy-D-glucose incorporation by AGS gastric adenocarcinoma cells in vitro during response to epirubicin, cisplatin and 5-fluorouracil.
    Br J Cancer, 97(7): 902-9. [Abstract] [Full-text]
43. Potential use of inhibitors of bacteria spore germination in the prophylactic treatment of anthrax and Clostridium difficile-associated disease.
    Expert Rev Anti Infect Ther, 5(5): 783-92. [Abstract] [Full-text]
44. French national survey of inpatient adverse events prospectively assessed with ward staff.
    Qual Saf Health Care, 16(5): 369-77. [Abstract] [Full-text]
45. Compressed matrix core tablet as a quick/slow dual-component delivery system containing ibuprofen.
    AAPS PharmSciTech, 8(3): E76. [Abstract] [Full-text]
46. Evolution of hepatitis B serological markers in HIV-infected patients receiving highly active antiretroviral therapy.
    Clin Infect Dis, 45(9): 1221-9. [Abstract] [Full-text]
47. How older Vietnamese Australian women manage their medicines.
    J Cross Cult Gerontol, 22(4): 405-19. [Abstract] [Full-text]
48. Melphalan and prednisone plus thalidomide versus melphalan and prednisone alone or reduced-intensity autologous stem cell transplantation in elderly patients with multiple myeloma (IFM 99-06): a randomised trial.
    Lancet, 370(9594): 1209-18. [Abstract] [Full-text]
49. Treatment of unprotected left main coronary artery stenosis in a 5-year-old heart transplant patient using a sirolimus-eluting stent.
    J Heart Lung Transplant, 26(10): 1061-4. [Abstract] [Full-text]
50. Chemotherapy and survival for patients with multiple myeloma: findings from a large nationwide and population-based cohort.
    Am J Clin Oncol, 30(5): 540-8. [Abstract] [Full-text]
51. COX-2 and NF-KB overexpression is common in pancreatic cancer but does not predict for COX-2 inhibitors activity in combination with gemcitabine and oxaliplatin.
    Am J Clin Oncol, 30(5): 526-30. [Abstract] [Full-text]
52. Paclitaxel, carboplatin, 5-fluorouracil, and radiation for locally advanced esophageal cancer: phase II results of preliminary pharmacologic and molecular efforts to mitigate toxicity and predict outcomes: North Central Cancer Treatment Group (N0044).
    Am J Clin Oncol, 30(5): 507-13. [Abstract] [Full-text]
53. A phase I dose escalation study of biweekly gemcitabine and carboplatin in completely resected stage IB-IIIA nonsmall cell lung cancer.
    Am J Clin Oncol, 30(5): 498-502. [Abstract] [Full-text]
54. Phase I study of biweekly paclitaxel and carboplatin for frail patients with advanced non-small cell lung cancer.
    Am J Clin Oncol, 30(5): 487-91. [Abstract] [Full-text]
55. Dose escalating study of biweekly gemcitabine and carboplatin in patients with advanced cancer.
    Am J Clin Oncol, 30(5): 481-6. [Abstract] [Full-text]
56. Serum PSA half-life as a predictor of survival for hormone-refractory prostate cancer patients: modelization using a standardized set of response criteria.
    Prostate, 67(14): 1543-9. [Abstract] [Full-text]
57. Intravitreal bevacizumab vs verteporfin photodynamic therapy for neovascular age-related macular degeneration.
    Arch Ophthalmol, 125(10): 1357-61. [Abstract] [Full-text]
58. Hormone replacement therapy and lung cancer risk in Chinese.
    Cancer, 110(8): 1768-75. [Abstract] [Full-text]
59. Generic products of antiepileptic drugs (AEDs): is it an issue?
    Epilepsia, 48(10): 1825-32. [Abstract] [Full-text]
60. Impact of remission induction chemotherapy on survival in older adults with acute myeloid leukemia.
    Cancer, 110(8): 1752-9. [Abstract] [Full-text]
61. Improved efficacy of a licensed acellular pertussis vaccine, reformulated in an adjuvant emulsion of liposomes in oil, in a murine model.
    Clin Vaccine Immunol, 14(10): 1381-3. [Abstract] [Full-text]
62. Improving outcome of human immunodeficiency virus-infected patients in a Mexican intensive care unit.
    Arch Med Res, 38(8): 827-33. [Abstract] [Full-text]
63. Cisplatin plus gemcitabine or vinorelbine for elderly patients with advanced non small-cell lung cancer: the MILES-2P studies.
    J Clin Oncol, 25(29): 4663-9. [Abstract] [Full-text]
64. Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors.
    J Clin Oncol, 25(29): 4603-9. [Abstract] [Full-text]
65. Concurrent chemotherapy and intensity-modulated radiation therapy for anal canal cancer patients: a multicenter experience.
    J Clin Oncol, 25(29): 4581-6. [Abstract] [Full-text]
66. Pharmacogenetic assessment of toxicity and outcome after platinum plus taxane chemotherapy in ovarian cancer: the Scottish Randomised Trial in Ovarian Cancer.
    J Clin Oncol, 25(29): 4528-35. [Abstract] [Full-text]
67. Gemtuzumab ozogamicin in combination with attenuated doses of standard induction chemotherapy can successfully induce complete remission without increasing toxicity in patients with acute myeloid leukemia aged 55 or older.
    Eur J Haematol, 79(5): 398-404. [Abstract] [Full-text]
68. Randomized phase II study of erlotinib combined with bevacizumab compared with bevacizumab alone in metastatic renal cell cancer.
    J Clin Oncol, 25(29): 4536-41. [Abstract] [Full-text]
69. Randomized phase II trial of cetuximab, bevacizumab, and irinotecan compared with cetuximab and bevacizumab alone in irinotecan-refractory colorectal cancer: the BOND-2 study.
    J Clin Oncol, 25(29): 4557-61. [Abstract] [Full-text]
70. End points for colon cancer adjuvant trials: observations and recommendations based on individual patient data from 20,898 patients enrolled onto 18 randomized trials from the ACCENT Group.
    J Clin Oncol, 25(29): 4569-74. [Abstract] [Full-text]
71. Drug selection errors in relation to medication labels: a simulation study.
    Anaesthesia, 62(11): 1090-4. [Abstract] [Full-text]
72. HER2 and response to paclitaxel in node-positive breast cancer.
    N Engl J Med, 357(15): 1496-506. [Abstract] [Full-text]
73. Look-alike medications: a formula for possible morbidity and mortality in the long-term care facility.
    J Am Med Dir Assoc, 8(8): 541-2. [Abstract] [Full-text]
74. Influence of acetaminophen vehicle on regulation of transporter gene expression during hepatotoxicity.
    J Toxicol Environ Health A, 70(21): 1870-2. [Abstract] [Full-text]
75. Guidelines for the management of patients on oral anticoagulants requiring dental surgery.
    Br Dent J, 203(7): 389-93. [Abstract] [Full-text]
76. Race/ethnicity and nonadherence to prescription medications among seniors: results of a national study.
    J Gen Intern Med, 22(11): 1572-8. [Abstract] [Full-text]
77. Vascular targeted photodynamic therapy with palladium-bacteriopheophorbide photosensitizer for recurrent prostate cancer following definitive radiation therapy: assessment of safety and treatment response.
    J Urol, 178(5): 1974-9; discussion 1979. [Abstract] [Full-text]
78. Intensive treatment with methotrexate in early rheumatoid arthritis: aiming for remission. Computer Assisted Management in Early Rheumatoid Arthritis (CAMERA, an open-label strategy trial).
    Ann Rheum Dis, 66(11): 1443-9. [Abstract] [Full-text]
79. Where does the Occluded Artery Trial leave the late open artery hypothesis?
    Heart, 93(11): 1319-21. [Abstract] [Full-text]
80. Lamotrigine extended-release as adjunctive therapy for partial seizures.
    Neurology, 69(16): 1610-8. [Abstract] [Full-text]
81. Gefitinib inhibition of drug resistance to doxorubicin by inactivating ABCG2 in thyroid cancer cell lines.
    Arch Otolaryngol Head Neck Surg, 133(10): 1022-7. [Abstract] [Full-text]
82. Diamond at the nanoscale: applications of diamond nanoparticles from cellular biomarkers to quantum computing.
    Philos Transact A Math Phys Eng Sci, 365(1861): 2845-61. [Abstract] [Full-text]
83. Advances in solid dosage form manufacturing technology.
    Philos Transact A Math Phys Eng Sci, 365(1861): 2935-49. [Abstract] [Full-text]
84. Rational selection of patients for antibacterial prophylaxis after chemotherapy.
    J Clin Oncol, 25(30): 4821-8. [Abstract] [Full-text]
85. Phase II study of low-dose paclitaxel and cisplatin in combination with split-course concomitant twice-daily reirradiation in recurrent squamous cell carcinoma of the head and neck: results of Radiation Therapy Oncology Group Protocol 9911.
    J Clin Oncol, 25(30): 4800-5. [Abstract] [Full-text]
86. Phase II trial of sunitinib in patients with metastatic colorectal cancer after failure of standard therapy.
    J Clin Oncol, 25(30): 4793-9. [Abstract] [Full-text]
87. Capecitabine plus erlotinib in gemcitabine-refractory advanced pancreatic cancer.
    J Clin Oncol, 25(30): 4787-92. [Abstract] [Full-text]
88. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: results from the BICC-C Study.
    J Clin Oncol, 25(30): 4779-86. [Abstract] [Full-text]
89. Comparison of menopausal symptoms during the first year of adjuvant therapy with either exemestane or tamoxifen in early breast cancer: report of a Tamoxifen Exemestane Adjuvant Multicenter trial substudy.
    J Clin Oncol, 25(30): 4765-71. [Abstract] [Full-text]
90. Long-term survival associated with complete resection after induction chemotherapy in stage IIIA (N2) and IIIB (T4N0-1) non small-cell lung cancer patients: the Spanish Lung Cancer Group Trial 9901.
    J Clin Oncol, 25(30): 4736-42. [Abstract] [Full-text]
91. Combined immunochemotherapy with reduced whole-brain radiotherapy for newly diagnosed primary CNS lymphoma.
    J Clin Oncol, 25(30): 4730-5. [Abstract] [Full-text]
92. Bevacizumab plus irinotecan in recurrent glioblastoma multiforme.
    J Clin Oncol, 25(30): 4722-9. [Abstract] [Full-text]
93. Predicting treatment response of malignant gliomas to bevacizumab and irinotecan by imaging proliferation with [18F] fluorothymidine positron emission tomography: a pilot study.
    J Clin Oncol, 25(30): 4714-21. [Abstract] [Full-text]
94. Evaluation of alternate size descriptors for dose calculation of anticancer drugs in the obese.
    J Clin Oncol, 25(30): 4707-13. [Abstract] [Full-text]
95. Epigenetic targets in hematological malignancies: combination therapies with HDACis and demethylating agents.
    Expert Rev Anticancer Ther, 7(10): 1439-49. [Abstract] [Full-text]
96. New targets for non-small-cell lung cancer therapy.
    Expert Rev Anticancer Ther, 7(10): 1423-37. [Abstract] [Full-text]
97. Survey of drug-related problems identified by community pharmacies.
    Ann Pharmacother, 41(11): 1825-32. [Abstract] [Full-text]
98. Adherence analysis using visual analog scale versus claims-based estimation.
    Ann Pharmacother, 41(11): 1792-7. [Abstract] [Full-text]
99. Phase II study of efficacy and safety of bevacizumab in combination with chemotherapy or erlotinib compared with chemotherapy alone for treatment of recurrent or refractory non small-cell lung cancer.
    J Clin Oncol, 25(30): 4743-50. [Abstract] [Full-text]
100. Sustained delivery of IL-1 Ra from biodegradable microspheres reduces the number of murine B16 melanoma lung metastases.
     J Control Release, 123(2): 123-30. [Abstract] [Full-text]
101. Tumoral acidic extracellular pH targeting of pH-responsive MPEG-poly(beta-amino ester) block copolymer micelles for cancer therapy.
     J Control Release, 123(2): 109-15. [Abstract] [Full-text]
102. The utility of cyclodextrins for enhancing oral bioavailability.
     J Control Release, 123(2): 78-99. [Abstract] [Full-text]
103. Resorbable polymer microchips releasing BCNU inhibit tumor growth in the rat 9L flank model.
     J Control Release, 123(2): 172-8. [Abstract] [Full-text]
104. On the design of in situ forming biodegradable parenteral depot systems based on insulin loaded dialkylaminoalkyl-amine-poly(vinyl alcohol)-g-poly(lactide-co-glycolide) nanoparticles.
     J Control Release, 123(2): 131-40. [Abstract] [Full-text]
105. Long-term recovery of the human corneal endothelium after toxic injury by benzalkonium chloride.
     Br J Ophthalmol, 91(11): 1460-3. [Abstract] [Full-text]
106. One-year results of the SCORPIUS study: a German multicenter investigation on the effectiveness of sirolimus-eluting stents in diabetic patients.
     J Am Coll Cardiol, 50(17): 1627-34. [Abstract] [Full-text]
107. A vision of individualized medicine in the context of global health.
     Clin Pharmacol Ther, 82(5): 491-3. [Abstract] [Full-text]
108. Treatment of metastatic Ewing sarcoma/primitive neuroectodermal tumor of bone: evaluation of increasing the dose intensity of chemotherapy--a report from the Children's Oncology Group.
     Pediatr Blood Cancer, 49(7): 894-900. [Abstract] [Full-text]
109. High-grade astrocytoma in very young children.
     Pediatr Blood Cancer, 49(7): 888-93. [Abstract] [Full-text]
110. Results of a multicenter retrospective study of a combined medical and surgical approach to pulmonary aspergillosis in pediatric neutropenic patients.
     Pediatr Blood Cancer, 49(7): 909-13. [Abstract] [Full-text]
111. High-dose therapy and autologous stem cell transplantation for children with HIV-associated non-Hodgkin lymphoma.
     Pediatr Blood Cancer, 49(7): 984-7. [Abstract] [Full-text]
112. Oral drug therapy for multiple neglected tropical diseases: a systematic review.
     JAMA, 298(16): 1911-24. [Abstract] [Full-text]
113. Clinical outcomes and CD4 cell response in children receiving antiretroviral therapy at primary health care facilities in Zambia.
     JAMA, 298(16): 1888-99. [Abstract] [Full-text]
114. Postoperative pneumonia after major pulmonary resections: an unsolved problem in thoracic surgery.
     Ann Thorac Surg, 84(5): 1669-73. [Abstract] [Full-text]
115. Cancer chemotherapy in young children: challenges and solutions.
     Pediatr Blood Cancer, 49(7): 1091-2. [Abstract] [Full-text]
116. Role of platinum agents in the management of advanced pancreatic cancer.
     Expert Opin Pharmacother, 8(16): 2719-27. [Abstract] [Full-text]
117. Gradations of researchers' obligation to provide ancillary care for HIV/AIDS in developing countries.
     Am J Public Health, 97(11): 1956-61. [Abstract] [Full-text]
118. A peptide dendrimer enzyme model with a single catalytic site at the core.
     J Am Chem Soc, 129(43): 13238-46. [Abstract] [Full-text]
119. Cisplatin and fluorouracil alone or with docetaxel in head and neck cancer.
     N Engl J Med, 357(17): 1705-15. [Abstract] [Full-text]
120. Cisplatin, fluorouracil, and docetaxel in unresectable head and neck cancer.
     N Engl J Med, 357(17): 1695-704. [Abstract] [Full-text]
121. Single-center experience with foam sclerotherapy without ultrasound guidance for treatment of varicose veins.
     Dermatol Surg, 33(11): 1334-9; discussion 1339. [Abstract] [Full-text]
122. Intraperitoneal photodynamic therapy for an ovarian cancer ascite model in Fischer 344 rat using hematoporphyrin monomethyl ether.
     Cancer Sci, 98(12): 1959-64. [Abstract] [Full-text]
123. Electroporation-based DNA immunisation: translation to the clinic.
     Expert Opin Biol Ther, 7(11): 1647-64. [Abstract] [Full-text]
124. Influence of phosphorus dendrimers on the aggregation of the prion peptide PrP 185-208.
     Biochem Biophys Res Commun, 364(1): 20-5. [Abstract] [Full-text]
125. Primary anaplastic large cell lymphoma of the lung. Report of two cases and literature review.
     Acta Haematol, 118(3): 188-91. [Abstract] [Full-text]
126. Rapid fluid resuscitation in pediatrics: testing the American College of Critical Care Medicine guideline.
     Ann Emerg Med, 50(5): 601-7. [Abstract] [Full-text]
127. Low-dose mitomycin C as a prophylaxis for corneal haze in myopic surface ablation.
     Am J Ophthalmol, 144(5): 673-681. [Abstract] [Full-text]
128. In vitro and in vivo antitumor effects of doxorubicin loaded with bacterial magnetosomes (DBMs) on H22 cells: the magnetic bio-nanoparticles as drug carriers.
     Cancer Lett, 258(1): 109-17. [Abstract] [Full-text]
129. Quantitative double-fluorescence immunohistochemistry (qDFIHC), a novel technology to assess protein expression: a pilot study analyzing 5-FU sensitive markers thymidylate synthase, dihydropyrimidine dehydrogenase and orotate phosphoribosyl transferases in gastric cancer tissue specimens.
     Cancer Lett, 258(1): 45-54. [Abstract] [Full-text]
130. Patterns and predictors of changes in adherence to highly active antiretroviral therapy: longitudinal study of men and women.
     Clin Infect Dis, 45(10): 1377-85. [Abstract] [Full-text]
131. Adjuvant glycerol and/or dexamethasone to improve the outcomes of childhood bacterial meningitis: a prospective, randomized, double-blind, placebo-controlled trial.
     Clin Infect Dis, 45(10): 1277-86. [Abstract] [Full-text]
132. Catheter-directed Venous Thrombolysis in acute iliofemoral vein thrombosis--the CaVenT study: rationale and design of a multicenter, randomized, controlled, clinical trial (NCT00251771).
     Am Heart J, 154(5): 808-14. [Abstract] [Full-text]
133. Timing of recanalization after microbubble-enhanced intravenous thrombolysis in basilar artery occlusion.
     Stroke, 38(11): 2931-4. [Abstract] [Full-text]
134. Improving the capture of adverse event data in clinical trials: the role of the International Atomic Energy Agency.
     Int J Radiat Oncol Biol Phys, 69(4): 1218-21. [Abstract] [Full-text]
135. Back to basics: how natural products can provide the basis for new therapeutics.
     Expert Opin Investig Drugs, 16(11): 1753-73. [Abstract] [Full-text]
136. Neuropsychological outcomes from a randomized trial of triple intrathecal chemotherapy compared with 18 Gy cranial radiation as CNS treatment in acute lymphoblastic leukemia: findings from Dana-Farber Cancer Institute ALL Consortium Protocol 95-01.
     J Clin Oncol, 25(31): 4914-21. [Abstract] [Full-text]
137. Assessment of response to induction therapy and its influence on 5-year failure-free survival in group III rhabdomyosarcoma: the Intergroup Rhabdomyosarcoma Study-IV experience--a report from the Soft Tissue Sarcoma Committee of the Children's Oncology Group.
     J Clin Oncol, 25(31): 4909-13. [Abstract] [Full-text]
138. Imatinib inhibits colorectal cancer cell growth and suppresses stromal-induced growth stimulation, MT1-MMP expression and pro-MMP2 activation.
     Int J Cancer, 121(12): 2808-14. [Abstract] [Full-text]
139. (99m)Tc-MIBI imaging for prediction of therapeutic effects of second-generation MDR1 inhibitors in malignant brain tumors.
     Int J Cancer, 121(12): 2637-45. [Abstract] [Full-text]
140. Identification of a subset of pericytes that respond to combination therapy targeting PDGF and VEGF signaling.
     Int J Cancer, 121(12): 2606-14. [Abstract] [Full-text]

© 2004-2012 Chemotherapy Research Today. All Rights Reserved.